Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 14.13%, which has investors questioning if this is right time ...

Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial ...

A downtrend has been apparent in Inhibikase Therapeutics, Inc. (IKT) lately. While the stock has lost 15.4% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was ...

H.C. Wainwright analyst Edward White reiterated a Hold rating on Inhibikase Therapeutics (IKT – Research Report) today. The company’s shares ...

INHIBIKASE THERAPEUTICS ($IKT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company ...

Assess today's live Inhibikase Therapeutics Inc (IKT) share price, performance and insights using our live NASDAQ: IKT stock exchange data. Analyse the historical data and Inhibikase Therapeutics Inc ...

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ...